Company facts
- Headquarters
- Emeryville, California
- Most recent report
- 10-Q, filed Aug 10, 2026
- Filings on record
- 148 filings
- On EDGAR
- CIK 1785279
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer Smaller reporting company Emerging growth company
Financials 8 of 11
News 8 of 22
Prospectuses and Registrations 8 of 9
- S-8 Registration statement for an employee plan Mar 5, 2026
- S-3 Shelf registration statement Mar 17, 2025
- S-8 Registration statement for an employee plan Mar 17, 2025
- 424B4 Final prospectus for an offering Feb 12, 2024
- S-8 Registration statement for an employee plan Feb 9, 2024
- S-1/A Registration statement for an offering, amended Feb 7, 2024
- S-1/A Registration statement for an offering, amended Feb 5, 2024
- S-1/A Registration statement for an offering, amended Jan 8, 2024
Proxies 4
Ownership 8 of 73
- 4 Insider reported a trade Jun 11, 2026
- 4 Insider reported a trade Jun 11, 2026
- 4 Insider reported a trade Jun 11, 2026
- 4 Insider reported a trade Jun 11, 2026
- 4 Insider reported a trade Jun 10, 2026
- 4 Insider reported a trade Jun 10, 2026
- 4 Insider reported a trade Jun 10, 2026
- 4 Insider reported a trade Apr 3, 2026
Other 8 of 29
- ARS Annual report sent to shareholders Apr 27, 2026
- ARS Annual report sent to shareholders Apr 28, 2025
- EFFECT Notice that a registration became effective Mar 25, 2025
- CORRESP Reply to SEC staff Mar 21, 2025
- UPLOAD Comment letter from SEC staff Mar 21, 2025
- SEC STAFF LETTER Feb 8, 2024
- EFFECT Notice that a registration became effective Feb 8, 2024
- CERT Exchange certified a listing Feb 8, 2024
Everything here comes from Metagenomi Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.